ECSP16093323A - N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida - Google Patents

N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida

Info

Publication number
ECSP16093323A
ECSP16093323A ECIEPI201693323A ECPI201693323A ECSP16093323A EC SP16093323 A ECSP16093323 A EC SP16093323A EC IEPI201693323 A ECIEPI201693323 A EC IEPI201693323A EC PI201693323 A ECPI201693323 A EC PI201693323A EC SP16093323 A ECSP16093323 A EC SP16093323A
Authority
EC
Ecuador
Prior art keywords
cyanomethyl
benzamide
pyrimidin
morpholinophenylamine
morpholinophenylamino
Prior art date
Application number
ECIEPI201693323A
Other languages
English (en)
Inventor
Dimitrios Stefanidis
Henry Morrison
Matthew Warr
Fang Wang
James Whitney
Brandon Brown
Jeffrey Hemenway
Ernest Carra
Yan Xin
Bing Shi
Troy Reynolds
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16093323(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ECSP16093323A publication Critical patent/ECSP16093323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas de sales nuevas y estables de N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida que son adecuadas para la preparación de formulaciones farmacéuticas de las mismas y su uso terapéutico.
ECIEPI201693323A 2014-06-12 2016-12-09 N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida ECSP16093323A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12

Publications (1)

Publication Number Publication Date
ECSP16093323A true ECSP16093323A (es) 2017-01-31

Family

ID=53674249

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201693323A ECSP16093323A (es) 2014-06-12 2016-12-09 N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida

Country Status (36)

Country Link
US (5) US9469613B2 (es)
EP (3) EP3154950B1 (es)
JP (5) JP6600649B2 (es)
KR (1) KR101928225B1 (es)
CN (2) CN110627728A (es)
AP (1) AP2016009551A0 (es)
AR (1) AR100818A1 (es)
AU (1) AU2015274554B9 (es)
BR (1) BR112016028749A2 (es)
CA (1) CA2951883C (es)
CR (1) CR20160575A (es)
CU (1) CU20160183A7 (es)
CY (2) CY1123604T1 (es)
DK (1) DK3154950T3 (es)
EA (1) EA032639B1 (es)
EC (1) ECSP16093323A (es)
ES (1) ES2822773T3 (es)
FI (1) FIC20240025I1 (es)
FR (1) FR24C1030I2 (es)
HR (1) HRP20201492T1 (es)
HU (2) HUE051360T2 (es)
IL (3) IL249038B (es)
LT (2) LT3154950T (es)
MA (1) MA40067A (es)
MX (3) MX374541B (es)
NL (1) NL301282I2 (es)
NZ (1) NZ725966A (es)
PH (1) PH12016502461A1 (es)
PL (1) PL3154950T3 (es)
PT (1) PT3154950T (es)
RS (1) RS61065B1 (es)
SG (2) SG10201911925TA (es)
SI (1) SI3154950T1 (es)
TW (3) TWI729644B (es)
UY (1) UY36166A (es)
WO (1) WO2015191846A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10245268B2 (en) 2016-08-10 2019-04-02 Sierra Oncology, Inc. Treatment of ACVR1-mediated diseases
JP7550393B2 (ja) * 2018-05-15 2024-09-13 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
US11963962B2 (en) 2018-08-21 2024-04-23 Glaxosmithkline Llc Platelet count-agnostic methods of treating myelofibrosis
WO2020167845A1 (en) * 2019-02-12 2020-08-20 Impact Biomedicines, Inc. Crystalline forms of a jak2 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP4376849A1 (en) 2021-07-30 2024-06-05 GlaxoSmithKline LLC Biomarker and patient selection in treatment for myelofibrosis
CN117794546A (zh) 2021-08-10 2024-03-29 葛兰素史密斯克莱有限责任公司 莫洛替尼组合疗法
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115957221B (zh) * 2021-10-09 2026-01-06 广东东阳光药业股份有限公司 抗纤维化组合物
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
JP2004528295A (ja) 2001-01-30 2004-09-16 サイトピア ピーティワイ リミテッド キナーゼ阻害方法
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
JP2005511502A (ja) 2001-09-12 2005-04-28 ヴィレックス リサーチ インコーポレイテッド 固定化した血小板結合剤を有する血管閉塞固相剤
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003286876A1 (en) 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2004041814A1 (en) 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as jak inhibitors
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
KR20070084067A (ko) 2004-10-13 2007-08-24 와이어쓰 Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
AU2007220047B2 (en) 2006-02-28 2013-08-01 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
CA2732791A1 (en) 2008-08-05 2010-02-11 Targegen, Inc. Methods of treating thalassemia
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8580749B2 (en) 2009-06-05 2013-11-12 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
CA2819560A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
AP2013007281A0 (en) 2011-05-02 2013-11-30 Ym Biosciences Australia Pty Multiple myeloma treatment
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
MX2015008829A (es) 2013-01-09 2016-04-25 Concert Pharmaceuticals Inc Momelotinib deuterado.
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Also Published As

Publication number Publication date
JP7550205B2 (ja) 2024-09-12
EP3154950A1 (en) 2017-04-19
NL301282I2 (nl) 2025-03-12
CY1123604T1 (el) 2022-03-24
CY2024024I2 (el) 2025-03-28
NZ725966A (en) 2018-04-27
HUS2400025I1 (hu) 2024-08-28
IL276948B (en) 2021-09-30
MX2016016294A (es) 2017-09-01
HUE051360T2 (hu) 2021-03-01
LTPA2024523I1 (es) 2024-07-25
JP2021107465A (ja) 2021-07-29
AR100818A1 (es) 2016-11-02
CU20160183A7 (es) 2017-05-10
PH12016502461A1 (en) 2017-03-06
MX2022015558A (es) 2023-01-30
TW202012378A (zh) 2020-04-01
FIC20240025I1 (fi) 2024-07-12
MX2019009564A (es) 2019-10-02
AP2016009551A0 (en) 2016-11-30
SG10201911925TA (en) 2020-01-30
USRE49445E1 (en) 2023-03-07
JP6840909B2 (ja) 2021-03-10
ES2822773T3 (es) 2021-05-04
IL286442A (en) 2021-10-31
EA201692356A1 (ru) 2017-07-31
JP2023021454A (ja) 2023-02-10
CY2024024I1 (el) 2025-03-28
JP2017517535A (ja) 2017-06-29
IL249038B (en) 2020-09-30
US20160347719A1 (en) 2016-12-01
JP2018184486A (ja) 2018-11-22
JP2020059759A (ja) 2020-04-16
EP3907219A1 (en) 2021-11-10
AU2015274554B9 (en) 2018-04-19
CA2951883A1 (en) 2015-12-17
LT3154950T (lt) 2020-11-25
CN110627728A (zh) 2019-12-31
UY36166A (es) 2016-01-29
EA032639B1 (ru) 2019-06-28
MA40067A (fr) 2015-12-17
US9469613B2 (en) 2016-10-18
PL3154950T3 (pl) 2021-01-25
CN106458929A (zh) 2017-02-22
SI3154950T1 (sl) 2021-01-29
USRE50497E1 (en) 2025-07-22
FR24C1030I2 (fr) 2025-06-13
BR112016028749A2 (pt) 2017-08-22
EP3154950B1 (en) 2020-08-05
TW201617323A (zh) 2016-05-16
US20150361050A1 (en) 2015-12-17
DK3154950T3 (da) 2020-09-14
JP6600649B2 (ja) 2019-10-30
WO2015191846A1 (en) 2015-12-17
IL276948A (en) 2020-10-29
CR20160575A (es) 2017-01-20
FR24C1030I1 (fr) 2024-08-30
AU2015274554B2 (en) 2018-02-15
USRE48285E1 (en) 2020-10-27
TWI729644B (zh) 2021-06-01
IL249038A0 (en) 2017-01-31
HRP20201492T1 (hr) 2021-01-08
KR101928225B1 (ko) 2018-12-11
CA2951883C (en) 2020-05-05
US9809559B2 (en) 2017-11-07
JP6883560B2 (ja) 2021-06-09
KR20170015496A (ko) 2017-02-08
EP3719005A1 (en) 2020-10-07
JP7198867B2 (ja) 2023-01-04
RS61065B1 (sr) 2020-12-31
MX374541B (es) 2025-03-06
PT3154950T (pt) 2020-10-09
AU2015274554A1 (en) 2016-11-24
TW202134236A (zh) 2021-09-16
TWI681954B (zh) 2020-01-11
SG11201610079VA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
DK3265084T3 (da) Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
MX2015003140A (es) Formulaciones de enzalutamida.
EA201691582A1 (ru) Новые фармацевтические препараты
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
MX2017000134A (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3 ,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carb oxamida.
CR20150549A (es) Compuestos heterocíclicos y sus usos
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
CO2018001756A2 (es) Concentrados en suspensión aceitosa con baja separación gravimétrica y baja viscosidad
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
ECSP16074478A (es) Compuestos novedosos
MX386584B (es) Composiciones de liberación retardada de linaclotida.
SV2018005776A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida
BR112017010402A2 (pt) carboxamida substituída à base de tiazol e oxazol e derivados de ureia como ligantes de receptor vanilóide ii
CY1123267T1 (el) Κρυσταλλικες μορφες 2-(tpit-boytyλamino)-4-((1r,3r,4r)-3-yδpoξy-4-μεθυλοκυκλοεξυλαμινο)-πυριμιδινο-5-καρβοξαμιδιου
EP3845644C0 (en) NEW HUMAN SERUM ALBUMIN MUTANT
EP3394099A4 (en) Formulations of Manipulated Anti- IL-10 Antibodies
HUE040093T2 (hu) Ibuprofén és tramadol gyógyászati kompozíciója szemgyógyászati alkalmazásra
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY35746A (es) Derivados de fenilalanina sustituidos
CO2019008110A2 (es) Activador de nrf2
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
CL2015003761A1 (es) Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.